1. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. Baltimore, MD: Williams & Wilkins; 1996. Methodology. xxxix–v.
2. Moskowitz SM, Chmiel JF, Sternen DL, et al. CFTR-related disorders (GeneReview) Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine; 2008. ( http://www.ncbi.nlm.nih.gov/books/NBK1250/). (Accessed December 24, 2010) 3. Cao A, Galanello R. Beta-thalassemia (GeneReview) Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine; 2010. ( http://www.ncbi.nlm.nih.gov/books/NBK1426/). (Accessed December 24, 2010) 4. Bender MA, Hobbs W. Sickle cell disease (GeneReview) Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine; 2009. ( http://www.ncbi.nlm.nih.gov/books/NBK1377/). (Accessed December 24, 2010) 5. Au KS, Ashley-Koch A, Northrup H. Epidemiologic and genetic aspects of spina bifida and other neural tube defects. Dev Disabil Res Rev. 2010;16(1):6–15. [PMC free article] [PubMed] 6. Mitchell JJ, Scriver CR. Phenylalanine hydroxylase deficiency (GeneReview) Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine; 2010. ( http://www.ncbi.nlm.nih.gov/books/NBK1504/). (Accessed December 24, 2010) 7. Prior TW, Russman BS. Spinal muscular atrophy (Gene Review) Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine; 2006. ( http://www.ncbi.nlm.nih.gov/books/NBK1352/). (Accessed December 24, 2010) 8. Kaback MM. Hexosaminidase A deficiency (GeneReview) Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine; 2006. ( http://www.ncbi.nlm.nih.gov/books/NBK1218/). (Accessed December 24, 2010) 9. Mégarbané A, Ravel A, Mircher C, et al. The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome. Genet Med. 2009;11(9):611–616. [PubMed] 10. Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med. 2003;348(1):50–58. [PubMed] 11. Evans JP, Dale DC, Fomous C. Preparing for a consumer-driven genomic age. N Engl J Med. 2010;363(12):1099–1103. [PubMed] 12. Feero WG, Guttmacher AE, Collins FS. Genomic medicine—an updated primer. N Engl J Med. 2010;362(21):2001–2011. [PubMed] 14. Poot M, Hochstenbach R. A three-step workflow procedure for the interpretation of array-based comparative genome hybridization results in patients with idiopathic mental retardation and congenital anomalies. Genet Med. 2010;12(8):478–485. [PubMed] 15. Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet. 2009;85(2):142–154. [PubMed] 16. Moore CA, Khoury MJ, Bradley LA. From genetics to genomics: using gene-based medicine to prevent disease and promote health in children. Semin Perinatol. 2005;29(3):135–143. [PubMed]
17. American College of Medical Genetics. Newborn Screening: Toward a Uniform Screening Panel and System. Rockville, MD: American College of Medical Genetics; 2005.
18. Rinaldo P, Lim JS, Tortorelli S, et al. Newborn screening of metabolic disorders: recent progress and future developments. Nestle Nutr Workshop Ser Pediatr Program. 2008;62:81–93. [PubMed] 19. National Newborn Screening and Genetics Resource Center. ( http://genes-r-us.uthscsa.edu/). Austin, TX: National Newborn Screening and Genetics Resource Center. (Accessed December 24, 2010) 20. Pass KA, Lane PA, Fernhoff PM, et al. US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN) J Pediatr. 2000;137(suppl 4):S1–S46. [PubMed]
21. Folling A. Excretion of phenylpyruvic acid in urine as a metabolic anomaly in connection with imbecility. Nord Med Tidskr. 1934;8:1054–1059.
22. Armstrong MD, Tyler FH. Studies on phenylketonuria. I. Restricted phenylalanine intake in phenylketonuria. J Clin Invest. 1955;34(4):565–580. [PMC free article] [PubMed] 23. Horner FA, Streamer CW. Effect of a phenylalanine-restricted diet on patients with phenylketonuria; clinical observations in three cases. J Am Med Assoc. 1956;161(17):1628–1630. [PubMed] 24. Bickel H, Gerrard J, Hickmans EM. Influence of phenylalanine intake on phenylketonuria. Lancet. 1953;265(6790):812–813. [PubMed] 25. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338–343. [PubMed]
26. Paul DB. The Politics of Heredity. Albany, NY: State University of New York Press; 1998. pp. 173–186.
27. Paul DB. Patient advocacy in newborn screening: continuities and discontinuities. Am J Med Genet C Semin Med Genet. 2008;148C(1):8–14. [PubMed]
28. Committee for the Study of Inborn Errors of Metabolism. Genetic Screening: Programs, Principles, and Research. Washington, DC: National Academy of Sciences; 1975.
29. Brosco JP, Seider MI, Dunn AC. Universal newborn screening and adverse medical outcomes: a historical note. Ment Retard Dev Disabil Res Rev. 2006;12(4):262–269. [PubMed]
30. Kevles D. In the Name of Eugenics. Cambridge, United Kingdom: Harvard University Press; 1995.
31. American Academy of Pediatrics. Statement on compulsory testing of newborn infants for hereditary metabolic disorders. Pediatrics. 1967;39(4):623–624.
32. Lindee S. Moments of Truth in Genetic Medicine. Baltimore, MD: Johns Hopkins University Press; 2005. pp. 28–57.
33. National Institutes of Health Consensus Development Panel. Pediatrics. 4. 2001; 108(4). National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16–18, 2000; pp. 972–982.
34. Koch R, Burton B, Hoganson G, et al. Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis. 2002;25(5):333–346. [PubMed] 35. Matalon R, Michals K, Azen C, et al. Maternal PKU Collaborative Study: pregnancy outcome and postnatal head growth. J Inherit Metab Dis. 1994;17(3):353–355. [PubMed] 37. Rastogi MV, LaFranchi SH. Congenital hypothyroidism [review] Orphanet J Rare Dis. 2010;5:17. [PMC free article] [PubMed] 38. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986;314(25):1593–1599. [PubMed] 39. Consensus conference. Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA. 1987;258(9):1205–1209. [PubMed] 40. Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;53(RR-13):1–36. [PubMed] 41. Lai HJ, Cheng Y, Farrell PM. The survival advantage of patients with cystic fibrosis diagnosed through neonatal screening: evidence from the United States Cystic Fibrosis Foundation registry data. J Pediatr. 2005;147(suppl 3):S57–S63. [PubMed] 42. Grosse SD, Rosenfeld M, Devine OJ, et al. Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr. 2006;149(3):362–366. [PubMed] 43. Tluczek A, Becker T, Laxova A, et al. Relationships among health-related quality of life, pulmonary health, and newborn screening for cystic fibrosis [published online ahead of print November 24, 2010] Chest. doi: 10.1378/chest.10–1504. [PubMed] 44. Grosse SD, Boyle CA, Kenneson A, et al. From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics. 2006;117(3):923–929. [PubMed] 45. Wilcken B. The consequences of extended newborn screening programmes: do we know who needs treatment? J Inherit Metab Dis. 2008;31:173–177. [PubMed] 46. Botkin JR, Clayton EW, Fost NC, et al. Newborn screening technology: proceed with caution. Pediatrics. 2006;117(5):1793–1799. [PubMed] 47. Natowicz M. Newborn screening—setting evidence-based policy for protection. N Engl J Med. 2005;353(9):867–870. [PubMed] 48. Wilcken B. Rare diseases and the assessment of intervention: what sorts of clinical trials can we use? J Inherit Metab Dis. 2001;24(2):291–298. [PubMed] 52. Perrin JM, Knapp AA, Browning MF, et al. An evidence development process for newborn screening. Genet Med. 2010;12(3):131–134. [PubMed] 54. Alexander D, van Dyck PC. A vision of the future of newborn screening. Pediatrics. 2006;117(5 pt 2):S350–S354. [PubMed] 55. Bailey DB, Jr, Skinner D, Warren SF. Newborn screening for developmental disabilities: reframing presumptive benefit. Am J Public Health. 2005;95(11):1889–1893. [PubMed]
56. Cody JD. An advocate's perspective on newborn screening policy. In: Baily MA, Murray TH, editors. Ethics and Newborn Genetic Screening. Baltimore, MD: Johns Hopkins University Press; 2009. pp. 89–105.
57. Baily MA, Murray TH. Ethics, evidence, and cost in newborn screening. Hastings Cent Rep. 2008;38(3):23–31. [PubMed]
58. The President's Council on Bioethics. The Changing Moral Focus of Newborn Screening. Washington, DC: The President's Council on Bioethics; 2008.
59. Tluczek A, Orland KM, Nick SW, et al. Newborn screening: an appeal for improved parent education. J Perinat Neonatal Nurs. 2009;23(4):326–334. [PMC free article] [PubMed] 60. Davis TC, Humiston SG, Arnold CL, et al. Recommendations for effective newborn screening communication: results of focus groups with parents, providers, and experts. Pediatrics. 2006;117(5 pt 2):S326–S340. [PubMed] 61. Miller FA, Hayeems RZ, Carroll JC, et al. Consent for newborn screening: the attitudes of health care providers. Public Health Genomics. 2010;13(3):181–190. [PubMed] 62. Ross LF. Mandatory versus voluntary consent for newborn screening? Kennedy Inst Ethics J. 2010;20(4):299–328. [PubMed] 63. Schreiner F, Brack C, Salzgeber K, et al. False negative 17-hydroxyprogesterone screening in children with classical congenital adrenal hyperplasia. Eur J Pediatr. 2008;167(4):479–481. [PubMed] 64. Bhattacharya K, Khalili V, Wiley V, et al. Newborn screening may fail to identify intermediate forms of maple syrup urine disease. J Inherit Metab Dis. 2006;29(4):586. . (doi: 10.1007/s10545-006-0366-0) [PubMed] 65. Puckett RL, Lorey F, Rinaldo P, et al. Maple syrup urine disease: further evidence that newborn screening may fail to identify variant forms. Mol Genet Metab. 2010;100(2):136–142. [PubMed] 66. Frazier DM, Millington DS, McCandless SE, et al. The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005. J Inherit Metab Dis. 2006;29(1):76–85. [PubMed] 67. Tarini BA, Christakis DA, Welch HG. State newborn screening in the tandem mass spectrometry era: more tests, more false-positive results. Pediatrics. 2006;118(2):448–456. [PubMed] 68. Rinaldo P, Zafari S, Tortorelli S, et al. Making the case for objective performance metrics in newborn screening by tandem mass spectrometry. Ment Retard Dev Disabil Res Rev. 2006;12(4):255–261. [PubMed] 69. Tluczek A, Koscik RL, Farrell PM, et al. Psychosocial risk associated with newborn screening for cystic fibrosis: parents’ experience while awaiting the sweat-test appointment. Pediatrics. 2005;115(6):1692–1703. [PubMed] 70. Gurian EA, Kinnamon DD, Henry JJ, et al. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics. 2006;117(6):1915–1921. [PubMed] 71. Lipstein EA, Perrin JM, Waisbren SE, et al. Impact of false-positive newborn metabolic screening results on early health care utilization. Genet Med. 2009;11(10):716–721. [PMC free article] [PubMed] 72. Grosse SD, Khoury MJ, Greene CL, et al. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med. 2006;8(4):205–212. [PubMed] 73. Kemper AR, Knapp AA, Green NS, et al. Weighing the evidence for newborn screening for early-infantile Krabbe disease. Genet Med. 2010;12(9):539–543. [PubMed] 75. Borowitz D, Parad RB, Sharp JK, et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. Cystic Fibrosis Foundation. J Pediatr. 2009;155(suppl 6):S106–S116. [PubMed] 76. Timmermans S, Buchbinder M. Patients-in-waiting: living between sickness and health in the genomics era. J Health Soc Behav. 2010;51(4):408–423. [PubMed] 77. National Human Genome Research Institute. Summary of population-based carrier screening for single gene disorders: lessons learned and new opportunities. Bethesda, MD: National Human Genome Research Institute; ( http://www.genome.gov/27026048). (Accessed February 12, 2011) 78. Laird L, Dezateux C, Anionwu EN. Neonatal screening for sickle cell disorders: what about the carrier infants? BMJ. 1996;313(7054):407–411. [PMC free article] [PubMed] 79. Grossman LK, Holtzman NA, Charney E, et al. Neonatal screening and genetic counseling for sickle cell trait. Am J Dis Child. 1985;139(3):241–244. [PubMed] 80. Miller FA, Robert JS, Hayeems RZ. Questioning the consensus: managing carrier status results generated by newborn screening. Am J Public Health. 2009;99(2):210–215. [PubMed] 81. American Society of Human Genetics. Genetic counseling. Am J Hum Genet. 1975;27:240–242. [PubMed]
82. Michie S, Smith JA, Heaversedge J, et al. Genetic counseling: clinical geneticists’ views. J Genet Couns. 1999;8:275–285.
83. Clark RD, Fletcher J, Petersen G. Conceiving a fetus for bone marrow donation: an ethical problem in prenatal diagnosis. Prenat Diagn. 1989;9(5):329–334. [PubMed] 84. Nadler HL, Gerbie AB. Role of amniocentesis in the intrauterine detection of genetic disorders. N Engl J Med. 1970;282(11):596–599. [PubMed] 85. Kaback MM, Nathan TJ, Greenwald S. Tay-Sachs disease: heterozygote screening and prenatal diagnosis—U.S. experience and world perspective. Prog Clin Biol Res. 1977;18:13–36. [PubMed] 86. Wertz DC, Fletcher JC. Fatal knowledge? Prenatal diagnosis and sex selection. Hastings Cent Rep. 1989;19(3):21–27. [PubMed] 87. Parens E, Asch A. Disability rights critique of prenatal genetic testing: reflections and recommendations. Ment Retard Dev Disabil Res Rev. 2003;9(1):40–47. [PubMed] 88. Driscoll DA, Gross S. Clinical practice. Prenatal screening for aneuploidy. N Engl J Med. 2009;360(24):2556–2562. [PubMed] 89. Coleman M. Down's syndrome. Pediatr Ann. 1978;7(2):90–103. [PubMed] 90. Golbus MS, Loughman WD, Epstein CJ, et al. Prenatal genetic diagnosis in 3000 amniocenteses. N Engl J Med. 1979;300(4):157–163. [PubMed] 91. Scott R. Prenatal screening, autonomy and reasons: the relationship between the law of abortion and wrongful birth. Med Law Rev. 2003;11(3):265–325. [PubMed] 92. Klein RD, Mahoney MJ. Medical legal issues in prenatal diagnosis. Clin Perinatol. 2007;34(2):287–297. vi. [PubMed] 93. Brock DJ, Bolton AE, Monaghan JM. Prenatal diagnosis of anencephaly through maternal serum-alphafetoprotein measurement. Lancet. 1973;2(7835):923–924. [PubMed]
94. American College of Obstetrics and Gynecology. DPL Alert. Washington, DC: American College of Obstetricians and Gynecologists; 1985. Professional liability implications of AFP tests.
95. Annas GJ. Is a genetic screening test ready when the lawyers say it is? Hastings Cent Rep. 1985;15(6):16–18. [PubMed] 96. Merkatz IR, Nitowsky HM, Macri JN, et al. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol. 1984;148(7):886–894. [PubMed] 97. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol. 2007;110(6):1459–1467. [PubMed] 98. O'Brien JS, Okada S, Chen A, et al. Tay-Sachs disease. Detection of heterozygotes and homozygotes by serum hexosaminidase assay. N Engl J Med. 1970;283(1):15–20. [PubMed] 99. Cao A, Rosatelli MC, Monni G, et al. Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am. 2002;29(2):305–328. vi–vii. [PubMed]
100. Cowan RS. Heredity and Hope. Cambridge, MA: Harvard University Press; 2008. pp. 180–222.
101. Angastiniotis MA, Hadjiminas MG. Prevention of thalassaemia in Cyprus. Lancet. 1981;1(8216):369–371. [PubMed]
102. Wailoo K. Dying in the City of the Blues. Chapel Hill, NC: University of North Carolina Press; 2001.
103. Merkel H. Scientific advances and social risks: historical perspectives of genetic screening programs for sickle cell disease, Tay-Sachs disease, neural tube defects and Down syndrome, 1970–1997. In: Holtzman NA, Watson M, editors. Promoting Safe and Effective Genetic Testing in the United States. Baltimore, MD: Johns Hopkins University Press; 1999.
104. Bowman JE. Genetic screening programs and public policy. Phylon. 1977;38(2):117–142. [PubMed] 105. Bowman JE. Prenatal screening for hemoglobinopathies. Am J Hum Genet. 1991;48(3):433–438. [PubMed] 106. Ekstein J, Katzenstein H. The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Adv Genet. 2001;44:297–310. [PubMed] 107. ACOG Committee on Genetics. ACOG Committee opinion no. 442: preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol. 2009;114(4):950–953. [PubMed]
108. U.S. Preventive Services Task Force. In: Guide to Clinical Preventive Services. Baltimore, MD: Williams & Wilkins; 1996. Screening for hemoglobinopathies; pp. 485–494.
109. ACOG Committee on Obstetrics. ACOG practice bulletin no. 78: hemoglobinopathies in pregnancy. Obstet Gynecol. 2007;109(1):229–237. [PubMed] 110. Mennuti MT. Lights! Camera! Action! Obstet Gynecol. 2001;98(4):539–541. [PubMed] 111. Richards CS, Bradley LA, Amos J, et al. Standards and guidelines for CFTR mutation testing. Genet Med. 2002;4(5):379–391. [PubMed] 112. Committee on Genetics. American College of Obstetricians and Gynecologists. ACOG Committee opinion. Number 325, December 2005. Update on carrier screening for cystic fibrosis. Obstet Gynecol. 2005;106(6):1465–1468. [PubMed] 113. ACOG Committee on Genetics. ACOG Committee opinion no. 432: spinal muscular atrophy. Obstet Gynecol. 2009;113(5):1194–1196. [PubMed] 114. Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis. Arch Intern Med. 1999;159(14):1529–1539. [PubMed] 115. Morgan MA, Driscoll DA, Mennuti MT, et al. Practice patterns of obstetrician-gynecologists regarding preconception and prenatal screening for cystic fibrosis. Genet Med. 2004;6(5):450–455. [PubMed] 116. Hale JE, Parad RB, Comeau AM. Newborn screening showing decreasing incidence of cystic fibrosis. N Engl J Med. 2008;358(9):973–974. [PubMed] 117. Scotet V, Audrézet MP, Roussey M, et al. Impact of public health strategies on the birth prevalence of cystic fibrosis in Brittany, France. Hum Genet. 2003;113(3):280–285. [PubMed] 118. Massie J, Curnow L, Gaffney L, et al. Declining prevalence of cystic fibrosis since the introduction of newborn screening. Arch Dis Child. 2010;95(7):531–533. [PubMed] 119. Dupuis A, Hamilton D, Cole DE, et al. Cystic fibrosis birth rates in Canada: a decreasing trend since the onset of genetic testing. J Pediatr. 2005;147(3):312–315. [PubMed] 120. Slieker MG, Uiterwaal CS, Sinaasappel M, et al. Birth prevalence and survival in cystic fibrosis: a national cohort study in the Netherlands. Chest. 2005;128(4):2309–2315. [PubMed] 121. Castellani C, Picci L, Tamanini A, et al. Association between carrier screening and incidence of cystic fibrosis. JAMA. 2009;302(23):2573–2579. [PubMed] 122. Cheffins T, Chan A, Haan EA, et al. The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in south Australia. BJOG. 2000;107(12):1453–1459. [PubMed] 123. Ekelund CK, Jørgensen FS, Petersen OB, et al. Impact of a new national screening policy for Down's syndrome in Denmark: population based cohort study. Danish Fetal Medicine Research Group. BMJ. 2008;337:a2547. . (doi: 10.1136/bmj.a2547) [PMC free article] [PubMed] 124. Siffel C, Correa A, Cragan J, et al. Prenatal diagnosis, pregnancy terminations and prevalence of Down syndrome in Atlanta. Birth Defects Res A Clin Mol Teratol. 2004;70(9):565–571. [PubMed] 125. Khoshnood B, Pryde P, Blondel B, et al. Socioeconomic and state-level differences in prenatal diagnosis and live birth prevalence of Down's syndrome in the United States. Rev Epidemiol Sante Publique. 2003;51(6):617–627. [PubMed] 126. Binkert F, Mutter M, Schinzel A. Impact of prenatal diagnosis on the prevalence of live births with Down syndrome in the eastern half of Switzerland 1980–1996. Swiss Med Wkly. 2002;132(33-34):478–484. [PubMed] 127. Lai FM, Woo BH, Tan KH, et al. Birth prevalence of Down syndrome in Singapore from 1993 to 1998. Singapore Med J. 2002;43(2):70–76. [PubMed] 128. Verloes A, Gillerot Y, Van Maldergem L, et al. Major decrease in the incidence of trisomy 21 at birth in south Belgium: mass impact of triple test? Eur J Hum Genet. 2001;9(1):1–4. [PubMed] 129. Calda P, Sípek A, Gregor V. Gradual implementation of first trimester screening in a population with a prior screening strategy: population based cohort study. Acta Obstet Gynecol Scand. 2010;89(8):1029–1033. [PubMed] 130. Brajenović-Milić B, Prpić I, Petrović O, et al. The prevalence of live birth Down syndrome in the region of Primorsko-goranska County in Croatia, 1996–2005: the impact of screening and amniocentesis. Matern Child Health J. 2008;12(5):620–623. [PubMed] 131. Maya I, Davidov B, Gershovitz L, et al. Diagnostic utility of array-based comparative genomic hybridization (aCGH) in a prenatal setting. Prenat Diagn. 2010;30(12-13):1131–1137. [PubMed] 132. Van den Veyver IB, Patel A, Shaw CA, et al. Clinical use of array comparative genomic hybridization (aCGH) for prenatal diagnosis in 300 cases. Prenat Diagn. 2009;29(1):29–39. [PubMed] 133. Ogilvie CM, Yaron Y, Beaudet AL. Current controversies in prenatal diagnosis 3: for prenatal diagnosis, should we offer less or more than metaphase karyotyping? Prenat Diagn. 2009;29(1):11–14. [PubMed] 134. Liao GJ, Lun FM, Zheng YW, et al. Targeted massively parallel sequencing of maternal plasma DNA permits efficient and unbiased detection of fetal alleles. Clin Chem. 2011;57(1):92–101. [PubMed] 135. Roe AM, Shur N. From new screens to discovered genes: the successful past and promising present of single gene disorders. Am J Med Genet C Semin Med Genet. 2007;145C(1):77–86. [PubMed] 136. Bell CJ, Dinwiddie DL, Miller NA, et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med. 2011;3(65):65ra4. (doi: 10.1126/scitranslmed.3001756) [PubMed] 137. Surgeon General's family history initiative. Washington, DC: US Department of Health and Human Services. ( http://www.hhs.gov/familyhistory/). (Accessed December 24, 2010) 139. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005;143(5):355–361. [PubMed] 140. American Gastroenterological Association. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;121(1):195–197. [PubMed] 141. Linton MF, Fazio S. A practical approach to risk assessment to prevent coronary artery disease and its complications. National Cholesterol Education Program (NCEP)–the third Adult Treatment Panel (ATP III) Am J Cardiol. 2003;92(1A):19i–26i. [PubMed] 142. Valdez R, Yoon PW, Qureshi N, et al. Family history in public health practice: a genomic tool for disease prevention and health promotion. Annu Rev Public Health. 2010;31:69–87. [PubMed] 143. Ramsey SD, Clarke L, Etzioni R, et al. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001;135(8 pt 1):577–588. [PubMed] 144. Krawczak M, Cooper DN, Schmidtke J. Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet. 2001;69(2):361–370. [PubMed] 145. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375(9725):1525–1535. [PMC free article] [PubMed]
146. Welch HG, Shwartz LM, Woloshin S. Overdiagnosis: Making People Sick in the Pursuit of Health. Boston, MA: Beacon Press; 2011.